ESMO Congress 2022
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
MONARCH 3: trend for improved overall survival with abemaciclib plus aromatase inhibitor in advanced breast cancer
An interim analysis of phase III data further supports the use of abemaciclib plus non-steroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer
After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy
The PARP inhibitor shows durable clinical benefits in HRD+ patients with advanced disease reinforcing the importance of testing for BRCA mutations and/or HRD status.
The Society takes a further step toward improving oncologists’ knowledge on healthy lifestyles to better support their patients and reduce the burden of cancer